Statin-Induced Necrotizing Autoimmune Myopathy

Brent Gawey; Manasi Tannu; Jeeyon Rim; Laurence Sperling; Tracey L Henry

doi:10.1016/j.jaccas.2019.12.019

Statin-Induced Necrotizing Autoimmune Myopathy

JACC Case Rep. 2020 Feb 26;2(3):440-443. doi: 10.1016/j.jaccas.2019.12.019. eCollection 2020 Mar.

Authors

Brent Gawey¹, Manasi Tannu², Jeeyon Rim², Laurence Sperling³, Tracey L Henry⁴

Affiliations

¹ Department of Hospital Medicine, Emory University School of Medicine, Atlanta, Georgia.
² Department of Hospital Medicine, Emory University Hospital, Atlanta, Georgia.
³ Department of Preventative Cardiology, Emory Clinic, Atlanta, Georgia.
⁴ Divison of General Medicine and Geriatrics, Grady Memorial Hospital, Atlanta, Georgia.

Abstract

Statin-induced necrotizing autoimmune myopathy (SINAM) is an exceptionally rare yet devastating complication of statin therapy that can occur at any time after initiation. It should be considered in patients who develop proximal muscle weakness and marked elevated creatine phosphokinase while taking statin therapy. (Level of Difficulty: Beginner.).

Keywords: CPK, creatine phosphokinase; ELISA, enzyme-linked immunosorbent assay; HMGCR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase; IVIG, intravenous immune globulin; SINAM, statin-induced necrotizing autoimmune myopathy; autoimmune; myopathy; peripheral vascular disease; statins.

Publication types

Case Reports